<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hemangioblastoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hemangioblastoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hemangioblastoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric T Wong, MD, FANA, FAAN
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Joseph, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julian K Wu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 21, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemangioblastomas are uncommon, slow-growing tumors of the central nervous system, which most commonly occur in the cerebellum, brainstem, or spinal cord. They account for approximately 4 percent of all spinal cord tumors, and 7 to 10 percent of tumors arising in the posterior fossa in adults.
        </p>
        <p>
         Hemangioblastomas occur both sporadically and as an important component of von Hippel-Lindau (VHL) disease. VHL disease is an inherited, autosomal-dominant syndrome manifested by a variety of benign and malignant tumors, including hemangioblastomas, retinal angiomas, endolymphatic sac tumors, renal cell carcinoma (RCC), pheochromocytomas, pancreatic cysts, and neuroendocrine tumors.
        </p>
        <p>
         The clinical manifestations and management of patients with hemangioblastomas are reviewed here. The clinical manifestations and overall management of patients with VHL disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Sporadic versus VHL-associated tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemangioblastomas may occur either sporadically or as a manifestation of von Hippel-Lindau (VHL) disease. Although approximately 75 percent of all hemangioblastomas appear to be sporadic [
         <a href="#rid1">
          1
         </a>
         ], some of these may represent occult cases of VHL that can be detected if patients are appropriately screened for germline
         <em>
          VHL
         </em>
         pathogenic variants. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Hemangioblastomas'
         </a>
         .)
        </p>
        <p>
         Sporadic and VHL-related hemangioblastomas differ significantly in their presentation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sporadic hemangioblastomas are usually solitary. Thus, the presence of multiple tumors within the neuraxis should raise suspicion for VHL disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemangioblastomas associated with VHL are generally diagnosed at a younger age than sporadic tumors [
         <a href="#rid2">
          2
         </a>
         ]. In one series, the mean age at initial diagnosis was 29 years in patients with VHL, while the average age at presentation in those without VHL is one to two decades older [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with VHL disease, approximately one-half of tumors are in the spinal cord, 40 percent are in the cerebellum, and 10 percent are in the brainstem [
         <a href="#rid3">
          3
         </a>
         ]. Supratentorial lesions are rare. For those with sporadic tumors, isolated cerebellar lesions are substantially more common [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemangioblastomas can cause local symptoms by compression of neural structures, bleeding, or paraneoplastic complications. In patients with VHL disease, asymptomatic hemangioblastomas are diagnosed based upon imaging surveillance. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Surveillance protocols'
         </a>
         .)
        </p>
        <p>
         Hemangioblastomas can cause neurologic deficits by direct compression, edema, or tumor-associated hemorrhage.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The specific deficit from direct compression depends upon tumor location and may include dizziness/vertigo, cerebellar ataxia, oculomotor nerve dysfunction, dysphagia, motor weakness, or sensory deficits [
         <a href="#rid2">
          2
         </a>
         ]. Patients with spinal hemangioblastomas frequently present with pain [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute hemorrhage can be catastrophic. Intracerebral bleeding from a cerebellar hemangioblastoma may cause rapid obstructive hydrocephalus, cerebellar tonsillar herniation, or brainstem compression [
         <a href="#rid5">
          5,6
         </a>
         ]. Bleeding from a spinal hemangioblastoma may result in acute quadriplegia [
         <a href="#rid7">
          7
         </a>
         ], while headache, back pain, or radiculopathy may be caused by subarachnoid hemorrhage [
         <a href="#rid8">
          8,9
         </a>
         ]. In these situations, emergency neurosurgical intervention is indicated. The risk of bleeding in treated or untreated hemangioblastomas is unknown [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Paraneoplastic erythrocytosis has also been reported in patients with hemangioblastoma [
         <a href="#rid11">
          11,12
         </a>
         ]. The elevated hematocrit and red cell mass are a result of excessive erythropoietin production by the hemangioblastoma [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H928163645">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of hemangioblastomas occur in the posterior fossa, with 80 percent in the cerebellar hemispheres and 15 percent in the cerebellar vermis. The characteristic appearance on MRI is either that of an intra-axial cystic mass with an enhancing mural nodule abutting the pia or a solid, intensely enhancing mass, often with flow-voids from dilated vessels next to or within the tumor  (
         <a class="graphic graphic_diagnosticimage graphicRef140957" href="/z/d/graphic/140957.html" rel="external">
          image 1
         </a>
         ). Smaller hemangioblastomas (&lt;10 mm) may be isointense on T1-weighted images and hyperintense on T2-weighted images, with homogeneous contrast enhancement [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The majority of spinal hemangioblastomas are intramedullary, subpial, well-demarcated, and intensely enhancing masses with an associated syrinx [
         <a href="#rid4">
          4
         </a>
         ]. Multiple cord hemangioblastomas are more common in patients with VHL disease  (
         <a class="graphic graphic_diagnosticimage graphicRef140984" href="/z/d/graphic/140984.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H80503004">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preferred diagnostic procedure is gadolinium-enhanced magnetic resonance imaging (MRI). A computed tomography (CT) scan of the neuraxis is not an adequate diagnostic procedure because bone artifacts may obscure small tumors in the posterior fossa or spinal canal. For patients who cannot undergo an MRI, conventional angiography together with CT scanning are alternative diagnostic tests to define the location and vasculature feeding the hemangioblastoma.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          PATHOLOGY AND PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemangioblastomas are well-circumscribed, highly vascular red nodules that are often located within the walls of large cysts. On cross-section, these tumors appear beefy red due to their high vascularity and contrast with any adjacent pale cerebellar tissue  (
         <a class="graphic graphic_picture graphicRef60110" href="/z/d/graphic/60110.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         Microscopically, the two main components of both sporadic and von Hippel-Lindau (VHL)-associated hemangioblastomas are an extensive vascular network and the neoplastic "stromal cells"  (
         <a class="graphic graphic_picture graphicRef79080" href="/z/d/graphic/79080.html" rel="external">
          picture 2
         </a>
         ). The capillaries have a normal structure, including normal endothelial cells and pericytes. Neoplastic stromal cells, embedded among the vascular channels, have abundant cytoplasm packed with lipid vacuoles [
         <a href="#rid16">
          16
         </a>
         ]. The numerous lipid-containing vacuoles, which often impinge on the nucleus and scallop its edges, result in the typical "clear cell" morphology. These cells also have large nuclei that are often pleomorphic and hyperchromatic. Such nuclei are considered a degenerative feature rather than a sign of histologic grade, malignant potential or transformation [
         <a href="#rid17">
          17
         </a>
         ]. The mitotic rate is typically low. Where the tumor borders brain, it often forms intertwined small nodules with the host tissue and can occasionally manifest Rosenthal fibers in the adjacent tissue.
        </p>
        <p>
         Many of the clear-cell morphologic features of hemangioblastomas overlap with those of renal cell carcinomas (RCCs). RCCs, however, do not show the intimate relationship with the host brain tissue that can be found in a subset of hemangioblastomas, such as the intertwined nodules of brain, but instead have a border pushing against normal tissue. Since RCC is also a frequent manifestation of VHL disease and is histologically similar to hemangioblastomas, immunoperoxidase studies are typically necessary to distinguish these tumors. Unlike RCCs, hemangioblastomas do not have an epithelial origin and so do not typically express cytokeratins or epithelial membrane antigen (EMA), nor do they express CD10, PAX-2, or PAX-8. Furthermore, hemangioblastomas usually display immunoreactivity to inhibin, neuron-specific enolase (NSE), neural cell adhesion molecule 1 (NCAM-1), carbonic anhydrase IX, and D2-40, unlike RCCs  (
         <a class="graphic graphic_picture graphicRef69439" href="/z/d/graphic/69439.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid18">
          18-22
         </a>
         ].
        </p>
        <p>
         Retinal angiomas are hemangioblastomas that develop in the retina and within the optic nerve. If left untreated, retinal angiomas can hemorrhage, leading to retinal detachment, glaucoma, and loss of vision. Retinal angiomas are a frequent manifestation in patients with VHL disease. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Retinal capillary hemangioblastomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Molecular biology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inactivation of the VHL tumor suppressor (
         <em>
          VHL
         </em>
         ) gene, located on chromosome 3p, is involved in the pathogenesis of some sporadic as well as VHL-associated hemangioblastomas. Somatic mutations of the
         <em>
          VHL
         </em>
         gene and/or allelic deletion of the
         <em>
          VHL
         </em>
         gene may be present in as many as 50 percent of sporadic hemangioblastomas [
         <a href="#rid23">
          23-26
         </a>
         ]. Gain-of-function mutations in hypoxia-inducible factor-2 alpha (
         <em>
          HIF2A
         </em>
         ), which is regulated by
         <em>
          VHL
         </em>
         , have also been reported in sporadic tumors [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Hemangioblastomas'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">
          "Molecular biology and pathogenesis of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
         The genetic changes are found in the stromal elements but not in the vasculature [
         <a href="#rid24">
          24,28
         </a>
         ], suggesting that abnormal blood vessel formation might be caused by external factors produced by the stromal cells. In fact, expression of both erythropoietin and vascular endothelial growth factor (VEGF) is upregulated in the stromal cells of hemangioblastomas and may be involved in the pathogenesis of this disease [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemangioblastomas are highly vascular tumors that are often located in neurologically sensitive areas in the neuraxis  (
         <a class="graphic graphic_picture graphicRef60110" href="/z/d/graphic/60110.html" rel="external">
          picture 1
         </a>
         ). The anatomic location of the lesion plays an important role in determining the therapeutic approach. Patients are best managed in a multidisciplinary fashion with input from neurosurgeons, interventional neuroradiologists, radiation oncologists, and neurooncologists with expertise in central nervous system malignancies.
        </p>
        <p>
         For patients with von Hippel-Lindau (VHL) disease, multiple tumors are common, and therapeutic efforts should focus on avoiding treatment-related morbidity by minimizing the frequency of surgical interventions. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Hemangioblastomas'
         </a>
         .)
        </p>
        <p>
         Women with existing retinal, brain, and spinal cord lesions are at risk for tumor growth during pregnancy [
         <a href="#rid30">
          30
         </a>
         ]. A noncontrast magnetic resonance imaging (MRI) in the fourth month of pregnancy may be considered in these patients (see
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         ). Neuroimaging findings, along with clinical signs and symptoms, may be used to make decisions regarding the management of labor and delivery. (See
         <a class="medical medical_review" href="/z/d/html/4838.html" rel="external">
          "Neurologic disorders complicating pregnancy", section on 'Brain tumors'
         </a>
         .)
        </p>
        <p>
         Both surgical resection and radiation therapy (RT) have a role in the management of appropriately selected patients with sporadic tumors. The hypoxia inducible factor-2alpha (HIF-2alpha) inhibitor,
         <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">
          belzutifan
         </a>
         , is an additional option in patients with VHL-associated hemangioblastomas.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection offers definitive therapy for sporadic, isolated hemangioblastomas, particularly those arising in the cerebellum. The role of surgery in patients with VHL disease is less well defined because of the frequent occurrence of additional synchronous and metachronous lesions.
        </p>
        <p>
         Hemangioblastomas are highly vascular, and patients frequently need a preoperative angiogram to identify feeding arteries. For large lesions, embolization of feeding arteries with polymer microspheres, ethanol, or polyvinyl alcohol particles is typically performed prior to surgery  (
         <a class="graphic graphic_picture graphicRef55268" href="/z/d/graphic/55268.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid31">
          31-34
         </a>
         ]. Following preoperative embolization and using a microdissection technique with an intraoperative microscope, complete surgical resection of a hemangioblastoma is usually feasible with acceptable morbidity.
        </p>
        <p>
         The following contemporary series illustrate the outcomes following surgery for patients with hemangioblastomas in the cerebellum, spinal cord, and brainstem:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series from the National Institutes of Health (NIH), 80 patients with VHL underwent 126 operations, during which 164 cerebellar lesions were resected [
         <a href="#rid35">
          35
         </a>
         ]. Surgery was based upon the presence of symptoms (most frequently headache, ataxia, dysmetria, and hydrocephalus in 75, 55, 29, and 28 percent, respectively). Symptoms improved or stabilized in 98 percent of cases. Follow-up imaging at five years did not document any instances of recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a Japanese series, 40 of 48 patients with VHL and hemangioblastomas of the spinal cord required surgery, including seven patients who required two operations [
         <a href="#rid36">
          36
         </a>
         ]. Among the 48 patients, 46 (96 percent) had associated central nervous system lesions, primarily in the cerebellum. Resection of the spinal tumors resulted in improvement or stabilization of symptoms in 39 of 47 cases (83 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a French series, 34 patients (25 with VHL disease, 9 with sporadic lesions) underwent 40 operations, in which a total of 74 hemangioblastomas were resected [
         <a href="#rid37">
          37
         </a>
         ]. Tumors were located in the brainstem in 14 cases (19 percent) and the remainder were in the spinal cord, predominantly in the cervical and thoracic spine. At a mean follow-up of five years, 82 percent of patients were either improved or stabilized, while 18 percent were worse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a Japanese series of 36 patients with sporadic hemangioblastomas, gross total resection of the tumor was achieved in 31 of 36 patients [
         <a href="#rid38">
          38
         </a>
         ]. Younger age and cystic tumor characteristics were associated with a better prognosis. Notably, postoperative hemorrhage occurred in 4 of 19 patients with solid hemangioblastoma and in none of 17 patients with cystic tumors.
        </p>
        <p>
        </p>
        <p>
         The optimal timing of surgery for patients with a hemangioblastoma is uncertain. The risks associated with operative management include intraoperative bleeding and postoperative neurologic complications.
        </p>
        <p>
         The consensus among most neurosurgeons is to follow these patients with surveillance MRI scans of the neuraxis. If there is progression of neurologic symptoms, evidence of tumor or cyst growth, neurologic deficit, or hemorrhage, operative intervention should be considered.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there are no randomized clinical trials comparing RT with surgery in patients with hemangioblastomas, increasing data with relatively long follow-up support the role of RT, particularly for patients with multiple tumors and those with surgically inaccessible lesions [
         <a href="#rid39">
          39
         </a>
         ]. Most of the contemporary data come from series using stereotactic radiosurgery (SRS), although external beam RT (EBRT) or proton beam RT may be useful in selected cases.
        </p>
        <p>
         A systematic review of SRS treatment results published between 1990 and 2017 showed excellent tumor control at five-year follow-up [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Contemporary series illustrating the outcomes following RT include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 31 patients (26 with VHL), 92 intracranial and spinal hemangioblastomas were treated with SRS [
         <a href="#rid40">
          40
         </a>
         ]. At a median follow-up of 69 months, 84 percent of tumors were either unchanged or smaller, and the five-year local control rate was 82 percent. Lesion-associated symptoms were improved in 36 of 41 evaluable cases (88 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series that included 32 patients (13 with VHL disease), 74 intracranial hemangioblastomas were treated with SRS [
         <a href="#rid41">
          41
         </a>
         ]. On follow-up imaging, tumor control was achieved for 68 tumors (92 percent). Progression-free survival at five years was 90 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 18 patients (5 with VHL disease), 31 hemangioblastomas, including 20 in the cerebellum and 8 in the spinal cord, were treated with EBRT [
         <a href="#rid42">
          42
         </a>
         ]. Indications for therapy included recurrence after surgery, residual disease following surgery, or definitive therapy of the lesion in 12, 4, and 2 cases, respectively. With a median follow-up of 5 years, the 5- and 10-year overall survival rates were 69 and 30 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 21 patients (7 sporadic and 14 VHL) who underwent SRS for 57 hemangioblastomas, the actuarial tumor control rates after SRS were 94 and 80 percent at 5 and 10 years, respectively [
         <a href="#rid43">
          43
         </a>
         ]. Factors associated with longer tumor control on univariate analysis were solid tumor characteristics on imaging, small treatment volume, and tumors associated with VHL.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Antiangiogenic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the role of vascular endothelial growth factor (VEGF) in the formation of hemangioblastomas, inhibitors of angiogenesis (eg,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ) may offer a potential therapeutic approach for lesions not amenable to surgery or RT [
         <a href="#rid44">
          44
         </a>
         ]. Preliminary experience with this approach has been derived from the treatment of patients with retinal angiomas. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Retinal capillary hemangioblastomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1955130429">
         <span class="h2">
          When to refer for genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with more than one hemangioblastoma, the presence of other manifestations of VHL disease, or a family history of VHL should undergo genetic screening for germline
         <em>
          VHL
         </em>
         pathogenic variants  (
         <a class="graphic graphic_table graphicRef66320" href="/z/d/graphic/66320.html" rel="external">
          table 1
         </a>
         ). The likelihood of having a pathogenic variant in
         <em>
          VHL
         </em>
         varies inversely with age. Patients should be referred for appropriate genetic advice in conjunction with genetic testing. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Genetic screening is also suggested in patients with a single, seemingly sporadic hemangioblastoma, particularly those &lt;50 years of age. In such patients, the likelihood of having a germline
         <em>
          VHL
         </em>
         pathogenic variant or mosaic VHL is approximately 5 percent [
         <a href="#rid45">
          45
         </a>
         ]. The role of genetic testing, screening for related tumors, and surveillance  (
         <a class="graphic graphic_table graphicRef127959" href="/z/d/graphic/127959.html" rel="external">
          table 2
         </a>
         ) in these patients is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Hemangioblastomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4090322743">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Hemangioblastomas are uncommon, slow-growing tumors of the central nervous system, which most commonly occur in the cerebellum, brainstem, or spinal cord. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Association with von Hippel-Lindau disease
         </strong>
         – Hemangioblastomas occur both sporadically and as a component of von Hippel-Lindau (VHL) disease. Tumors associated with VHL disease are more likely to be multiple and present at a younger age compared with sporadic tumors. (See
         <a class="local">
          'Sporadic versus VHL-associated tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – Hemangioblastoma may be detected incidentally on imaging of the central nervous system (CNS), or they may come to attention based on neurologic deficits caused by direct compression, edema, or tumor-associated hemorrhage. (See
         <a class="local">
          'Symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroimaging
         </strong>
         – The characteristic magnetic resonance imaging (MRI) appearance of hemangioblastomas is an enhancing nodule associated with a cyst located in the cerebellum  (
         <a class="graphic graphic_diagnosticimage graphicRef140957" href="/z/d/graphic/140957.html" rel="external">
          image 1
         </a>
         ) or a homogeneously enhancing lesion on the surface of or within the spinal cord  (
         <a class="graphic graphic_diagnosticimage graphicRef140984" href="/z/d/graphic/140984.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="local">
          'Neuroimaging'
         </a>
         above and
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without known VHL disease
         </strong>
         – For patients without known VHL disease who present with a single suspected hemangioblastoma, we suggest surgery rather than observation both for treatment and to establish the diagnosis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Radiation therapy (RT) is an option for recurrent or residual disease if the risk of reoperation is high. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with VHL disease
         </strong>
         – For patients with known VHL disease, treatment decisions should be individualized and involve multidisciplinary input from neurosurgery, oncology, and radiation oncology. Observation is appropriate in many patients with asymptomatic tumors, and the hypoxia inducible factor-2alpha (HIF-2alpha) inhibitor,
         <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">
          belzutifan
         </a>
         , is now an option that may delay or avoid the need for surgery or RT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – All patients with more than one hemangioblastoma, the presence of other manifestations of VHL disease, or a family history of VHL should undergo genetic screening for germline
         <em>
          VHL
         </em>
         pathogenic variants  (
         <a class="graphic graphic_table graphicRef66320" href="/z/d/graphic/66320.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Genetic screening for VHL disease is also suggested in patients with a single hemangioblastoma without a family history of VHL, particularly those &lt;50 years of age. The risk of VHL disease in such patients is approximately 5 percent. (See
         <a class="local">
          'When to refer for genetic testing'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Neumann HP, Eggert HR, Weigel K, et al. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg 1989; 70:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takami H, Graffeo CS, Perry A, et al. Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas. J Neurooncol 2022; 159:221.
          </a>
         </li>
         <li class="breakAll">
          Aldape KD, Plate KH, Vortmeyer AO, et al. Hemangioblastoma. In: WHO Classification of Tumours of the Nervous System, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roonprapunt C, Silvera VM, Setton A, et al. Surgical management of isolated hemangioblastomas of the spinal cord. Neurosurgery 2001; 49:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakai S, Inoh S, Ueda Y, Nagai M. Hemangioblastoma presenting with intraparenchymatous hemorrhage. J Neurosurg 1984; 61:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adegbite AB, Rozdilsky B, Varughese G. Supratentorial capillary hemangioblastoma presenting with fatal spontaneous intracerebral hemorrhage. Neurosurgery 1983; 12:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu JS, Short MP, Schumacher J, et al. Intramedullary hemorrhage in spinal cord hemangioblastoma. Report of two cases. J Neurosurg 1994; 81:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerejo A, Vaz R, Feyo PB, Cruz C. Spinal cord hemangioblastoma with subarachnoid hemorrhage. Neurosurgery 1990; 27:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kormos RL, Tucker WS, Bilbao JM, et al. Subarachnoid hemorrhage due to a spinal cord hemangioblastoma: case report. Neurosurgery 1980; 6:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gläsker S, Van Velthoven V. Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery 2005; 57:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WALDMANN TA, LEVIN EH, BALDWIN M. The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. Am J Med 1961; 31:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zec N, Cera P, Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery 1991; 29:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kühne M, Sidler D, Hofer S, et al. Challenging manifestations of malignancies. Case 1. Polycythemia and high serum erythropoietin level as a result of hemangioblastoma. J Clin Oncol 2004; 22:3639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tachibana O, Yamashima T, Yamashita J. Immunohistochemical study of erythropoietin in cerebellar hemangioblastomas associated with secondary polycythemia. Neurosurgery 1991; 28:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu BC, Terae S, Hida K, et al. MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings. AJNR Am J Neuroradiol 2001; 22:206.
          </a>
         </li>
         <li class="breakAll">
          Bohling T, Hatva E, Plate KH, et al. von Hippel-Lindau disease and capillary haemangioblastoma. In: Pathology and Genetics of Tumors of the Nervous System, Kleihues P, Cavenee WK (Eds), International Agency for Research on Cancer, Lyon 1997.
         </li>
         <li class="breakAll">
          Burger PC, Scheithauer BW. Tumors of the Central Nervous System, Armed Forces Institute of Pathology, Washington 1994. p.239.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol 2005; 18:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney EM, Banerjee P, Ellis CL, et al. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol 2011; 35:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polydorides AD, Rosenblum MK, Edgar MA. Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med 2007; 131:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaller T, Bode M, Berlis A, et al. Specific immunohistochemical pattern of carbonic anhydrase IX is helpful for the diagnosis of CNS hemangioblastoma. Pathol Res Pract 2015; 211:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy S, Chu A, Trojanowski JQ, Zhang PJ. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol 2005; 109:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanno H, Kondo K, Ito S, et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54:4845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998; 58:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gläsker S, Bender BU, Apel TW, et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 2001; 70:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gijtenbeek JM, Jacobs B, Sprenger SH, et al. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg 2002; 97:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taïeb D, Barlier A, Yang C, et al. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. J Neurooncol 2016; 126:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997; 28:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998; 92:3388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frantzen C, Kruizinga RC, van Asselt SJ, et al. Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology 2012; 79:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskridge JM, McAuliffe W, Harris B, et al. Preoperative endovascular embolization of craniospinal hemangioblastomas. AJNR Am J Neuroradiol 1996; 17:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tampieri D, Leblanc R, TerBrugge K. Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery 1993; 33:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonser RR, Heiss JD, Oldfield EH. Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg 1998; 88:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vázquez-Añón V, Botella C, Beltrán A, et al. Preoperative embolization of solid cervicomedullary junction hemangioblastomas: report of two cases. Neuroradiology 1997; 39:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagannathan J, Lonser RR, Smith R, et al. Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2008; 108:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanno H, Yamamoto I, Nishikawa R, et al. Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord 2009; 47:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker F, Aghakhani N, Ducati LG, et al. Results of microsurgical treatment of medulla oblongata and spinal cord hemangioblastomas: a comparison of two distinct clinical patient groups. J Neurooncol 2009; 93:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda M, Takao T, Hiraishi T, et al. Clinical factors predicting outcomes after surgical resection for sporadic cerebellar hemangioblastomas. World Neurosurg 2014; 82:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan J, Jabarkheel R, Huang Y, et al. Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis. J Neurooncol 2018; 137:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss JM, Choi CY, Adler JR Jr, et al. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery 2009; 65:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kano H, Niranjan A, Mongia S, et al. The role of stereotactic radiosurgery for intracranial hemangioblastomas. Neurosurgery 2008; 63:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh ES, Nichol A, Millar BA, et al. Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys 2007; 69:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanakita S, Koga T, Shin M, et al. The long-term outcomes of radiosurgery for intracranial hemangioblastomas. Neuro Oncol 2014; 16:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riklin C, Seystahl K, Hofer S, et al. Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie 2012; 35:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodward ER, Wall K, Forsyth J, et al. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 2007; 130:836.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5209 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909683" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35902552" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35902552" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11504107" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Surgical management of isolated hemangioblastomas of the spinal cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6541682" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hemangioblastoma presenting with intraparenchymatous hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6682491" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Supratentorial capillary hemangioblastoma presenting with fatal spontaneous intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7965128" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intramedullary hemorrhage in spinal cord hemangioblastoma. Report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2274144" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Spinal cord hemangioblastoma with subarachnoid hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7191951" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Subarachnoid hemorrhage due to a spinal cord hemangioblastoma: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15987542" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk of hemorrhage in hemangioblastomas of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13782653" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1870685" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Extramedullary hematopoiesis in cerebellar hemangioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337812" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Challenging manifestations of malignancies. Case 1. Polycythemia and high serum erythropoietin level as a result of hemangioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1994278" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Immunohistochemical study of erythropoietin in cerebellar hemangioblastomas associated with secondary polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158911" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158911" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158911" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578072" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21263247" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17425399" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25888144" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Specific immunohistochemical pattern of carbonic anhydrase IX is helpful for the diagnosis of CNS hemangioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15864611" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8069849" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9458097" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309459" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12405390" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26514359" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9158701" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787178" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22875085" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8881249" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Preoperative endovascular embolization of craniospinal hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413884" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Preoperative embolization of brain and spinal hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9576266" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Tumor devascularization by intratumoral ethanol injection during surgery. Technical note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9045967" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Preoperative embolization of solid cervicomedullary junction hemangioblastomas: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18240914" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19030009" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Spinal cord hemangioblastomas in von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19430890" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Results of microsurgical treatment of medulla oblongata and spinal cord hemangioblastomas: a comparison of two distinct clinical patient groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24937595" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical factors predicting outcomes after surgical resection for sporadic cerebellar hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29204841" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19574828" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18812955" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The role of stereotactic radiosurgery for intracranial hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17869023" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335701" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The long-term outcomes of radiosurgery for intracranial hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846977" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antiangiogenic treatment for multiple CNS hemangioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264095" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
